Loading
A phase 2/3 trial of Fianlimab, Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) is a phase 2/3 interventional study registered as NCT05785767 by Regeneron Pharmaceuticals, with 149 participants enrolled, started 2023-06-30 and due to reach its primary completion in 2027-09-28. Interventions recorded: fianlimab, cemiplimab, Placebo. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Regeneron, PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/